Cash conversion has deteriorated as operating cash flow turned negative relative to net income (OCF/NI -0.17) and FCF margin fell to -3.9% in 2026Q4, yet cumulative OCF of $2.09B over ten quarters underscores cyclical earnings quality.
Cal-Maine Foods, Inc. (CALM) cash flow statement — 30-year operating, investing & financing cash flows
| Metric | May'26 | May'25 | May'24 | May'23 | May'22 | May'21 | May'20 | May'19 | May'18 | May'17 | May'16 | May'15 | May'14 | May'13 | May'12 | May'11 | May'10 | May'09 | May'08 | May'07 | May'06 | May'05 | May'04 | May'03 | May'02 | May'01 | May'00 | May'99 | May'98 | May'97 |
|---|
| Cash from Operations | 483.01M | 1.23B | 451.4M | 863.01M | 126.21M | 26.14M | 73.61M | 115.08M | 200.41M | -49.32M | 381.84M | 195.33M | 123.92M | 57.54M | 98.06M | 62.31M | 116.67M | 111.28M | 158.42M | 59.72M | 20.93M | 9.61M | 85.14M | 30.73M | 264K | 30.42M | -11.07M | 24.1M | 24.9M | 32.5M |
| Operating CF Margin % | 16.59% | 28.83% | 19.4% | 27.43% | 7.1% | 1.94% | 5.45% | 8.45% | 13.33% | -4.59% | 20.01% | 12.39% | 8.6% | 4.47% | 8.81% | 6.61% | 12.82% | 11.98% | 17.3% | 9.99% | 4.38% | 2.56% | 14.88% | 7.93% | 0.08% | 8.49% | -3.85% | 8.37% | 8.06% | 11.11% |
| Operating CF Growth % | -60.69% | 172.22% | -47.69% | 583.79% | 382.89% | -64.49% | -36.04% | -42.58% | 506.39% | -112.92% | 95.48% | 57.63% | 115.37% | -41.32% | 57.37% | -46.59% | 4.84% | -29.75% | 165.25% | 185.34% | 117.71% | -88.71% | 177.04% | 11540.53% | -99.13% | 374.92% | -145.92% | -3.21% | -23.38% | 28.46% |
| Net Income | 316.68M | 1.22B | 277.89M | 756.73M | 132.44M | 2.06M | 18.33M | 55.06M | 126.2M | -74.43M | 318.05M | 162.28M | 109.81M | 50.76M | 89.97M | 58.27M | 65.53M | 79.5M | 151.86M | 36.66M | -1.01M | -10.36M | 66.44M | 12.21M | -10.57M | 6.82M | -17.38M | 5.1M | 5.4M | 14.8M |
| Depreciation & Amortization | 124.34M | 94.02M | 80.24M | 72.23M | 68.39M | 59.48M | 58.1M | 54.65M | 54.03M | 49.11M | 44.59M | 40.71M | 37.2M | 34.17M | 30.75M | 30.75M | 31.79M | 28.08M | 25.32M | 21.48M | 20.57M | 16.44M | 16.84M | 16.62M | 17.31M | 17.54M | 15.81M | 12.2M | 12M | 10.6M |
| Stock-Based Compensation | 0 | 0 | 4.36M | 4.21M | 4.06M | 3.78M | 3.62M | 3.62M | 3.47M | 3.43M | 3.07M | 2.27M | 1.27M | 411K | -702K | -2.39M | -533K | -2.72M | 1.65M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Deferred Taxes | 67.36M | 11.57M | -9.67M | 24.47M | 5.68M | 22.35M | 10.28M | 6.12M | -33.81M | 14.83M | 19.39M | 5.11M | 7.63M | -5.75M | 5.33M | 10.35M | 2.07M | 11.04M | 3.66M | 1.21M | 985K | -710K | 3.55M | 7.04M | 241K | 3.41M | -4.71M | -100K | 800K | 2.9M |
| Other Non-Cash Items | 6.01M | 6.33M | -3.01M | -1.49M | -5.27M | 4.53M | 3.6M | -3.76M | -1.29M | 2.06M | -7.38M | -2.42M | -2.48M | -2.32M | -46.35M | -8.64M | -3.49M | -2.87M | -4.37M | 196K | 768K | -511K | -6.23M | -769K | 290K | 62K | -1.24M | -600K | 0 | -300K |
| Working Capital Changes | -31.4M | -103.19M | 101.6M | 6.86M | -79.09M | -66.06M | -20.32M | -612K | 51.83M | -44.33M | 4.11M | -12.62M | -29.51M | -19.74M | 19.06M | -26.03M | 21.3M | -1.73M | -19.71M | 191K | -378K | 4.75M | 4.54M | -4.37M | -7M | 2.59M | -3.54M | 7.5M | 6.7M | 4.5M |
| Change in Receivables | 139.75M | -105M | -27.57M | 58.13M | -93.9M | -33.49M | -17.68M | 16.01M | -28.38M | -37.22M | 21.16M | -18.96M | -2.28M | -21.67M | 0 | 0 | 13.11M | -3.58M | 0 | 0 | 3.24M | 4.83M | 0 | 0 | -7.39M | 2.3M | -3.82M | 1.9M | -300K | 1.7M |
| Change in Inventory | -34.98M | -12.22M | 28.8M | -21.1M | -36.15M | -31.16M | -9.7M | -2.29M | -7.95M | 2.39M | -8.54M | -143K | 8.91M | -6.38M | -7.14M | -16.11M | 5.31M | -2.91M | -14.56M | 47K | 2.14M | 3.62M | -756K | -4.9M | 1.01M | -3.21M | 1.42M | 6M | 3.7M | 1.2M |
| Change in Payables | -8.34M | 65.31M | 9.35M | -2.85M | 54.78M | -1.41M | 17.68M | -14.34M | 28.38M | -9.49M | -8.51M | 6.49M | -8.14M | 8.31M | 21.89M | 12.28M | 2.89M | 0 | 6.59M | 0 | 0 | 0 | 6.75M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cash from Investing | -507.14M | -579.52M | -412.59M | -375.11M | -117.02M | -44.19M | -61.37M | -47.82M | -163.85M | 56.13M | -212.55M | -141.63M | -99.38M | -88.34M | -27.05M | -30.61M | -61.55M | -122.49M | -31.34M | -49.27M | -22.87M | -23.66M | -44.03M | -11.81M | -14.38M | -12.96M | -59.97M | -26.8M | -18.1M | -20.6M |
| Capital Expenditures | -151.22M | -161.25M | -147.12M | -136.57M | -72.4M | -95.07M | -124.18M | -67.99M | -19.67M | -66.66M | -76.13M | -82.26M | -59.19M | -26.29M | -26.84M | -20.74M | -20.79M | -26.11M | -31.69M | -23.47M | -12.37M | -11.98M | -10.67M | -12.55M | -15.55M | -14.06M | -27.92M | -28.1M | -18.6M | -16.2M |
| CapEx % of Revenue | 5.19% | 3.78% | 6.32% | 4.34% | 4.07% | 7.05% | 9.19% | 4.99% | 1.31% | 6.2% | 3.99% | 5.22% | 4.11% | 2.04% | 2.41% | 2.2% | 2.28% | 2.81% | 3.46% | 3.92% | 2.59% | 3.19% | 1.86% | 3.24% | 4.77% | 3.92% | 9.73% | 9.76% | 6.02% | 5.54% |
| Acquisitions | -452.24M | -112.31M | -54.11M | -1.67M | -47.82M | 3.39M | -44.65M | -22.16M | -4.1M | -105.72M | -33.96M | -8.16M | -11.55M | -74.91M | 0 | 1.91M | -508K | -91.22M | -12.05M | -12.05M | -23.76M | 879K | 0 | 0 | 0 | 0 | -35.58M | 0 | 0 | 0 |
| Investments | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Other Investing | 0 | 0 | 3.27M | 2.08M | 8.74M | 6.66M | 10.42M | 9.48M | 7.54M | 6.67M | 8.29M | 4.52M | 5.82M | 6.47M | 39.42M | 8.42M | 6.95M | 128K | 15.05M | 754K | 2.88M | 1.36M | 3M | 734K | 1.18M | 1.1M | 3.53M | 1.3M | 500K | -4.4M |
| Cash from Financing | -362.75M | -386.72M | -93.76M | -254.16M | -7.46M | -2.72M | -3.36M | -46.45M | -5.7M | -18.3M | -148.91M | -59.55M | -35M | -41.34M | -31.56M | -73.48M | -22.55M | -16.76M | -47.26M | -8.72M | -4.99M | -17.25M | -10.57M | -17.7M | 5.86M | -10.88M | 41.38M | -2.2M | 10.6M | 7.9M |
| Debt Issued (Net) | 0 | -2.48M | -214K | -224K | -215K | -205K | -1.7M | -3.75M | -4.85M | -16.51M | -25.29M | -10.23M | -10.74M | -11.2M | -11.94M | -46.51M | -3.82M | 18.08M | -28.23M | -1.7M | -3.92M | -7.04M | -18.21M | -17.7M | 7.02M | -8.9M | -4.56M | 1.8M | 11.1M | -4M |
| Equity Issued (Net) | -131.12M | -53.95M | -1.69M | -1.64M | -1.13M | -871K | -910K | -985K | -1.13M | -1.72M | -1.76M | 531K | 279K | 380K | 318K | 143K | 0 | 427K | 626K | 262K | 103K | -9.03M | 8.38M | 0 | -571K | -1.37M | 46.55M | -3.5M | -200K | 10.2M |
| Dividends Paid | -231.62M | -330.29M | -91.86M | -252.29M | -6.12M | -1.65M | 0 | -41.71M | 0 | 0 | -120.94M | -48.91M | -24.53M | -30.52M | -19.94M | -24.88M | -19.04M | -35.27M | -19.65M | -1.17M | -1.17M | -1.18M | -746K | 0 | -591K | -607K | -611K | -600K | -300K | 0 |
| Share Repurchases | -131.12M | -53.95M | -1.69M | -1.64M | -1.13M | -871K | -910K | -985K | -1.13M | -1.72M | -1.76M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -9.34M | 0 | 0 | -571K | -1.37M | -1.24M | -3.5M | -300K | -400K |
| Other Financing | 0 | 0 | 0 | 0 | 3K | 5K | -755K | 0 | 279K | -73K | -918K | -940K | 0 | 0 | 0 | -2.23M | 308K | 0 | 0 | -6.1M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 100K | 0 | 1.7M |
| Net Change in Cash | -386.88M | 262.51M | -54.95M | 233.74M | 1.73M | -20.78M | 8.88M | 20.82M | 30.87M | -11.48M | 20.38M | -5.85M | -10.46M | -72.14M | 39.45M | -41.77M | 32.57M | -27.98M | 79.83M | 1.74M | -6.93M | -31.29M | 30.54M | 1.21M | -8.25M | 6.59M | -29.66M | -4.9M | 10.6M | 7.9M |
| Free Cash Flow | 331.79M | 1.07B | 304.28M | 726.44M | 53.81M | -68.93M | -50.57M | 47.1M | 180.74M | -115.97M | 305.71M | 113.07M | 64.73M | 31.25M | 71.21M | 41.57M | 95.88M | 85.17M | 126.73M | 36.25M | 8.56M | -2.36M | 74.47M | 18.18M | -15.29M | 16.36M | -38.99M | -4M | 6.3M | 16.3M |
| FCF Margin % | 11.4% | 25.05% | 13.08% | 23.09% | 3.03% | -5.11% | -3.74% | 3.46% | 12.03% | -10.79% | 16.02% | 7.17% | 4.49% | 2.43% | 6.4% | 4.41% | 10.53% | 9.17% | 13.84% | 6.06% | 1.79% | -0.63% | 13.01% | 4.69% | -4.69% | 4.57% | -13.58% | -1.39% | 2.04% | 5.57% |
| FCF Growth % | -68.92% | 250.84% | -58.11% | 1250.01% | 178.06% | -36.31% | -207.37% | -73.94% | 255.85% | -137.94% | 170.38% | 74.67% | 107.16% | -56.12% | 71.32% | -56.65% | 12.58% | -32.79% | 249.58% | 323.55% | 462.21% | -103.17% | 309.49% | 218.95% | -193.43% | 141.97% | -874.7% | -163.49% | -61.35% | -1.21% |
| FCF per Share | 6.94 | 21.83 | 6.23 | 14.88 | 1.10 | -1.42 | -1.04 | 0.97 | 3.73 | -2.40 | 6.32 | 2.33 | 1.34 | 0.65 | 1.49 | 0.87 | 2.01 | 1.79 | 2.67 | 0.77 | 0.18 | -0.05 | 1.53 | 0.38 | -0.33 | 0.34 | -0.80 | -0.08 | 0.12 | 0.19 |
| FCF Conversion (FCF/Net Income) | 1.53x | 1.01x | 1.62x | 1.14x | 0.95x | 12.69x | 4.00x | 2.12x | 1.59x | 0.66x | 1.21x | 1.21x | 1.13x | 1.14x | 1.09x | 1.02x | 1.72x | 1.40x | 1.04x | 1.63x | -20.66x | -0.93x | 1.28x | 2.52x | -0.02x | 4.46x | 0.64x | 4.73x | 4.61x | 2.20x |
| Interest Paid | 0 | 0 | 0 | 561K | 379K | 508K | 498K | 644K | 0 | 0 | 1.07M | 2.31M | 3.15M | 3.54M | 4.41M | 6.45M | 6.88M | 6.16M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 426.17M | 35.1M | 258.25M | 1.75M | 995K | 32K | 36.31M | 0 | 0 | 166.84M | 75.53M | 41.63M | 42.67M | 27.07M | 28.93M | 14.38M | 42.34M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Quick answers to the most common questions about buying CALM stock.
Cal-Maine Foods, Inc. (CALM) generated $483.0M in net cash from operating activities in 2026. This reflects the cash generated directly from core business operations.
Cal-Maine Foods, Inc. (CALM) generated $331.8M in free cash flow in 2026. Free cash flow is the cash left over after capital expenditures, which can be used to pay dividends, repurchase shares, or pay down debt.
Cal-Maine Foods, Inc. (CALM) spent $151.2M on capital expenditures in 2026. CapEx represents the cash invested in physical assets like property, plant, and equipment to maintain or grow the business.
In 2026, Cal-Maine Foods, Inc. (CALM) returned $231.6M to shareholders via cash dividends and spent $131.1M on share repurchases. This shows the company's commitment to returning capital to its equity investors.
Key Metrics
Top Statement Risk
Egg price normalization
Metrics are mathematically derived from official filings.
Earnings Quality Deteriorates Sharply
Operating cash flow turned negative relative to net income in 2026Q4, with OCF/NI at -0.17, as reported in quarterly filings, signaling a breakdown in earnings quality.
The OCF/NI ratio swung from a healthy 2.05 in 2026Q3 to -0.17 in 2026Q4, indicating that reported losses are not fully reflecting cash generation. The negative working capital change of -$35.7M in 2026Q4 suggests that cash outflows are outpacing accrual-based earnings, likely due to inventory build-up or receivable collections. This divergence warrants close monitoring as it may indicate that the company is funding operations through cash reserves during a demand downturn.
Free Cash Flow Collapses Post-Peak
Free cash flow margin plummeted from 36.8% in 2025Q3 to -3.9% in 2026Q4, as per financial statements, reflecting the full unwinding of the HPAI-driven pricing windfall.
The FCF trajectory shows a dramatic reversal from a peak of $521.8M in 2025Q3 to a negative $21.4M in 2026Q4. This decline is consistent with the revenue normalization and margin compression observed in the income statement, where gross margins fell from 50.5% to 6.2%. The negative FCF in the latest quarter suggests that the company is now consuming cash, which may pressure its ability to maintain its variable dividend policy.
Capital Intensity Rises Amid Transition
CapEx as a percentage of revenue increased from 3.5% in 2025Q3 to 5.0% in 2026Q4, based on reported figures, indicating continued investment in cage-free conversion and flock replacement.
Despite the revenue decline, CapEx has remained relatively stable in absolute terms, ranging from $27.5M to $51.1M over the past ten quarters. This suggests that management is prioritizing long-term capacity and regulatory compliance over short-term cash preservation. The elevated capital intensity during a downturn may indicate that the company is positioning for the next upcycle, but it also increases the risk of cash burn if the demand environment remains weak.
Working Capital Swing Amplifies Volatility
Working capital changes swung from a positive $40.7M in 2025Q3 to a negative $120.2M in 2025Q2, as per quarterly data, highlighting the cyclicality of egg pricing and inventory.
The working capital line has been highly volatile, with large positive contributions during peak pricing quarters and significant outflows during troughs. In 2026Q4, the negative working capital change of -$35.7M suggests that the company is building inventory or facing slower collections as egg prices fall. This pattern indicates that cash flow is heavily influenced by commodity price cycles, making it difficult to predict short-term liquidity.
Capital Returns Persist Despite Cash Strain
Dividends and buybacks totaled $46.9M in 2026Q4, as reported, even as free cash flow turned negative, suggesting a commitment to shareholder returns despite cyclical pressures.
The company continued to pay dividends and repurchase shares in 2026Q4, with combined outflows of $46.9M, exceeding the negative FCF of -$21.4M. This indicates that management is drawing down cash reserves to maintain distributions, which may be unsustainable if the downturn persists. However, the fortress balance sheet with over $500M in cash provides a buffer, though investors should monitor whether the variable dividend policy will be adjusted in future quarters.
Cumulative Cash Generation Outpaces Earnings
Over the last ten quarters, cumulative operating cash flow of $2.09B exceeded cumulative net income of $1.99B, as per financial statements, indicating high earnings quality over the cycle.
Despite the recent deterioration, the cumulative OCF/NI ratio of 1.05 suggests that, on a multi-quarter basis, cash generation has been slightly stronger than reported earnings. This is partly due to non-cash charges like D&A and favorable working capital swings during peak quarters. However, the recent negative divergence in 2026Q4 may signal a turning point, and investors should watch whether the cumulative gap narrows further.
Cash Flow Obscures Biological Asset Costs
The cash flow statement does not separately disclose flock replacement costs, which are embedded in CapEx and COGS, as per standard accounting, potentially masking the true cost of maintaining production capacity.
Cal-Maine's biological assets (hens) are depreciated and replaced through CapEx, but the cash flow statement does not break out maintenance vs. growth CapEx. This makes it difficult to assess whether the company is adequately investing to sustain its flock, especially during periods of HPAI-related losses. Additionally, the timing of insurance recoveries and government indemnities may create lumpy cash inflows that are not indicative of core operations, as seen in prior quarters.